<DOC>
	<DOCNO>NCT00098436</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , temozolomide VNP40101M , work different way stop growth cancer cell , either kill cell stop dividing . Temozolomide may also help VNP40101M kill cancer cell make cancer cell sensitive drug . Giving temozolomide together VNP40101M may kill cancer cell . PURPOSE : This phase I trial study side effect best dose temozolomide VNP40101M treat patient relapsed refractory leukemia .</brief_summary>
	<brief_title>Temozolomide VNP40101M Treating Patients With Relapsed Refractory Leukemias</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose temozolomide VNP40101M patient relapse refractory leukemia . - Determine toxic effect regimen patient . OUTLINE : This open-label , dose-escalation , multicenter study . Patients receive oral temozolomide twice daily day 1-3 ( 5 dos ) follow VNP401010M IV 15-60 minute day 3 ( course 1 ) . Patients achieve complete partial response ≥ 50 % reduction bone marrow blast may receive second course therapy earlier day 43 . Courses may repeat approximately every 6 week discretion sponsor absence disease progression unacceptable toxicity . Cohorts 6 patient receive escalate dos temozolomide dose depletes leukemic blast AGT least 4 6 patient determine . Once dose determine , cohort 3-6 patient receive escalate dos VNP401010M maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Up 10 patient treated MTD . PROJECTED ACCRUAL : Approximately 25 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 following : Acute myeloid leukemia Acute lymphoblastic leukemia Chronic myelogenous leukemia blast crisis Relapsed refractory disease No known standard therapy anticipate result durable remission exist CNS leukemia allow PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy Not specify Hematopoietic Not specify Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) ALT AST ≤ 3 time ULN Chronic hepatitis allow Renal Creatinine ≤ 2.0 mg/dL Cardiovascular No active heart disease , include follow : Myocardial infarction within past 3 month Symptomatic coronary artery disease Arrhythmias control medication Uncontrolled congestive heart failure Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study participation No uncontrolled active infection PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Concurrent hydroxyurea allow within first 10 day study drug administration control elevate blast level platelet count Maximum hydroxyurea dose 5 g daily No persistent chronic toxic effect prior chemotherapy &gt; grade 1 Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other Recovered prior therapy At least 2 week since prior myelosuppressive cytotoxic agent ( absence rapidly progressive disease ) No 2 leukapheresis procedure within first 10 day study drug administration control elevate blast level platelet count No concurrent disulfiram No concurrent anticancer drug No concurrent standard investigational treatment leukemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
</DOC>